Figure 3.
Model assessing clinical risk according to MYC and BCL2 Status in DLBCL. The risk of treatment failure is proportional to the degree of MYC and BCL2 expression. The 5% of patients with the poorest outcome are shown in red and have the highest level of MYC and BCL expression as a result of translocation immunoglobulin loci. Reprinted from Sesques and Johnson75 with permission.